Get the Stockscreener App
514.06
7.58%
-42.16
After Hours:
517.94
3.88
+0.75%
Madrigal Pharmaceuticals Inc stock is traded at $514.06, with a volume of 682.40K.
It is down -7.58% in the last 24 hours and down -7.20% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$556.22
Open:
$554.99
24h Volume:
682.40K
Relative Volume:
1.98
Market Cap:
$11.68B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-20.46
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-13.44%
1M Performance:
-7.20%
6M Performance:
+66.58%
1Y Performance:
+54.19%
1-Day Range:
$511.03
$555.10
1-Week Range:
$511.03
$592.99
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
514.06 | 12.63B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
Pfizer inks licensing deal with Madrigal for MASH candidate - MSN
Madrigal’s $50M Pfizer Deal Sparks a New MASH Drug Power Play - MyChesCo
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum - Yahoo Finance
Madrigal expands its MASH pipeline - The Pharma Letter
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe DowngradeWhat's Changed - Yahoo Finance
Is Madrigal Pharmaceuticals Inc. stock a safe investment in uncertain marketsPortfolio Value Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Madrigal Pharmaceuticals (MDGL) Secures Global License for Ervog - GuruFocus
Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat - marketscreener.com
Pfizer in pact with Madrigal for MASH drug (MDGL:NASDAQ) - Seeking Alpha
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline - Investing.com
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline By Investing.com - Investing.com India
Madrigal Pharmaceuticals Expands Pipeline with Exclusive License Agreement for Ervogastat, Enhancing Leadership in MASH Therapies - Quiver Quantitative
Drug combo planned to target liver fat in patients with MASH - Stock Titan
What Madrigal Pharmaceuticals (MDGL)'s Valuation-Driven Analyst Downgrade Means For Shareholders - Sahm
US Stocks Recap: How Madrigal Pharmaceuticals Inc YDO1 stock trades pre earningsShare Buyback & Smart Swing Trading Alerts - moha.gov.vn
Is Madrigal Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Risk Managed Investment Entry Signals - ulpravda.ru
Is Madrigal Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Rallies & Community Trade Idea Sharing Platform - ulpravda.ru
Will Madrigal Pharmaceuticals Inc. stock deliver better than expected guidance - ulpravda.ru
How Madrigal Pharmaceuticals Inc. (YDO1) stock trades pre earningsJuly 2025 Highlights & Verified Momentum Watchlists - ulpravda.ru
Why Madrigal Pharmaceuticals stock slumped on Tuesday - MSN
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - Finviz
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.4%Time to Sell? - MarketBeat
Madrigal Pharmaceuticals (MDGL) Downgraded Amid Valuation Concer - GuruFocus
Wolfe Research downgrades Madrigal Pharmaceuticals stock on valuation concerns By Investing.com - Investing.com Canada
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - Finviz
Assessing Madrigal Pharmaceuticals (MDGL) Valuation As Rezdiffra Revenue Tops US$1b Amid Intensifying MASH Competition - Sahm
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade - Seeking Alpha
Madrigal Pharmaceuticals Earnings Notes - Trefis
MASH Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
(MDGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Madrigal Pharmaceuticals expands workforce with new equity grants to staff - MSN
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Madrigal uses equity incentives to lure talent as MASH drug scales up - MSN
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockLarge Cap Stability Picks & Consistently Superior Profits - earlytimes.in
Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up - MyChesCo
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight - MyChesCo
Madrigal Pharmaceuticals (MDGL) Is Up 5.4% After REZDIFFRA Phase 3 Data And CFO HireHas The Bull Case Changed? - Sahm
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week HighHere's What Happened - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD - Investing.com
Voya Investment Management LLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
(MDGL) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Bullish Rezdiffra Data, FDA Designations and Analyst Upgrades - Sahm
Trend Report: How strong is Madrigal Pharmaceuticals Inc stock revenue growthQuarterly Profit Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Madrigal Pharmaceuticals Stock Soars as Analysts Raise Price Targets - StocksToTrade
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):